Mismatch Repair in Methylated DNA

STRUCTURE AND ACTIVITY OF THE MISMATCH-SPECIFIC THYMINE GLYCOSYLASE DOMAIN OF METHYL-CpG-BINDING PROTEIN MBD4*

Peiying WuDagger , Chen QiuDagger §, Anjum Sohail||, Xing ZhangDagger , Ashok S. Bhagwat||, and Xiaodong ChengDagger **

From the Departments of Dagger  Biochemistry and § Chemistry, Emory University, Atlanta, Georgia 30322 and the || Department of Chemistry, Wayne State University, Detroit, Michigan 48202-3489

Received for publication, October 23, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

MBD4 is a member of the methyl-CpG-binding protein family. It contains two DNA binding domains, an amino-proximal methyl-CpG binding domain (MBD) and a C-terminal mismatch-specific glycosylase domain. Limited in vitro proteolysis of mouse MBD4 yields two stable fragments: a 139-residue fragment including the MBD, and the other 155-residue fragment including the glycosylase domain. Here we show that the latter fragment is active as a glycosylase on a DNA duplex containing a G:T mismatch within a CpG sequence context. The crystal structure confirmed the C-terminal domain is a member of the helix-hairpin-helix DNA glycosylase superfamily. The MBD4 active site is situated in a cleft that likely orients and binds DNA. Modeling studies suggest the mismatched target nucleotide will be flipped out into the active site where candidate residues for catalysis and substrate specificity are present.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

MBD4 is a mammalian DNA glycosylase that excises thymines from G:T mispairs and contains both a methyl-CpG binding domain (MBD)1 and a domain found in the Escherichia coli endonuclease III class of DNA glycosylases (1). It has preference for G:T mismatches within a CpG sequence context (1), and hence this enzyme can act upon G:T mismatches that result from the deamination of 5-methylcytosines (5mC) at CpG sites. The importance of this enzyme for mutation avoidance in mammals is confirmed by an increase in 5mC to T mutations in Mbd4-/- Big Blue mouse and by increased occurrence of colon carcinoma in Mbd4-/- ApcMin/+ mice (2). Additionally, studies of MBD4 (also called MED1) using the yeast two-hybrid system have shown that it interacts with MLH1 (a protein implicated in mismatch repair) and suggest a role for this enzyme in maintaining genome stability (3). Consistent with this observation, it is found that MBD4 is mutated in 26-43% of human colorectal tumors that show microsatellite instability (4).

MBD4 is not the only DNA glycosylase reported to excise thymines from G:T mismatches. Another enzyme, named thymine-DNA glycosylase (TDG), was identified earlier to have this ability (5). However, TDG is unrelated to MBD4 and belongs to the same structural superfamily as the uracil-excising enzymes UDG (6) and SMUG1 (7). MBD4 also differs from TDG in its substrate preference. Whereas the preferred substrates for TDG are N4-ethenocytosine or uracil paired with a G (8), MBD4 prefers thymine over N4-ethenocytosine (9). Recombinant MBD4 can also remove uracil, 5-fluorouracil, and 5mC at a low rate, particularly when these bases are opposite a guanine within CpG dinucleotides (1, 9, 10).

The MBD domain of MBD4 is similar to domains within four other mammalian proteins, MeCP2, MBD1, MBD2, and MBD3 (reviewed in Refs. 11 and 12). The latter proteins are involved in suppressing transcription in regions of heavy CpG methylation, but no such role has been ascribed to MBD4. Whereas the NMR structures of the MBD domains from MBD1 (13, 14) and MeCP2 (15) have been elucidated, no structural information regarding the glycosylase domain of MBD4 is available.

Here we present the crystal structure of the C-terminal glycosylase domain of MBD4, and we show that it belongs to the helix-hairpin-helix DNA glycosylase superfamily. The glycosylase domain alone is active on DNA duplex containing a G:T mismatch within a CpG sequence context.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Overexpression and Purification-- The full-length mouse MBD4 was expressed as a His-tagged fusion protein in vector pET6H (16). The four fragments of MBD4 (Fig. 1A), amino acids 49-187 (MBD domain), 400-554 (glycosylase domain or Delta 399), 49-554 (Delta 48), and 429-554 (Delta 428), were cloned into a modified pET28b (Novagen) vector, which contains an N-terminal tag of MGHHHHHH and accepts an NdeI-EcoRI insert. The Delta 428 fragment was also expressed as a GST fusion in pGEX2T vector (Amersham Biosciences). E. coli strain BL21(DE3) carrying respective plasmid was grown in LB media supplemented with appropriate antibiotics at 37 °C to A600 = 0.6, shifted to 22 °C, and induced with 0.4 mM isopropyl-1-thio-beta -D-galactopyranoside overnight at 22 °C, except that the full-length MBD4 was induced at 37 °C for 1 h.

The full-length and Delta 48 proteins were purified from cleared lysates using three successive chromatography steps as follows: a nickel chelate column, a HiTrap heparin column, and Superdex 200 (Amersham Biosciences). The proteins were stored in 20 mM potassium phosphate, pH 7.5, 1 mM EDTA, 0.1% 2-mercaptoethanol, and 0.2 M NaCl.

The MBD domain and the glycosylase domain were purified using nickel chelate, HiTrap Q, and Superdex 75 columns. The proteins were stored in a high salt buffer for crystallization (20 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, 5% glycerol, and 0.5 M NaCl) or in a low salt buffer for activity assay (20 mM Tris-HCl, pH 8.0, 1 mM EDTA, 1 mM DTT, 50% glycerol, and 50 mM NaCl).

The GST-Delta 428 was purified using glutathione-Sepharose 4B (Amersham Biosciences) and HiTrap Q column. The protein was stored in the low salt buffer.

Limited Proteolysis of Full-length MBD4 Protein-- Protease V8 was added, as described previously (17), to MBD4 for 15 min incubation at room temperature. Addition of the protease inhibitor 1-chloro-3-tosylamido-7-amino-2-heptanone stopped the reaction, and two major MBD4 fragments were observed via SDS-PAGE. The mass of the two fragments was determined by electrospray ionization mass spectrometry to be 15,353.5 and 18,537.2 Da. The N-terminal sequences of the two fragments were also determined. Combining these results allowed us to deduce that the fragments represent residues 49-187 (the MBD domain) and residues 400-554 (the C-terminal glycosylase domain) (Fig. 1A).

Crystallography-- Crystals of the MBD4 glycosylase domain stored in the high salt buffer were obtained in hanging drops under the conditions of 22-27% polyethylene glycol 2000 monomethyl ether, 190-230 mM ammonium sulfate, 10-15% ethylene glycol, 100 mM sodium citrate, pH 5.26. The initial drops were set up at 16 °C and moved to 4 °C after overnight incubation. Two crystal forms were observed, good looking diamond-shaped crystals appeared earlier at 16 °C but diffracted x-rays poorly. Rather unpromising colorless crystals appeared after 2-3 weeks only at 4 °C, but these diffracted x-rays strongly and belonged to space group P3121, based on the systematic absence of reflections along the z axis. There is one molecule per asymmetric unit, and unit cell dimensions were a = b = 48.58 Å and c = 146.57 Å.

Selenomethionine-containing glycosylase domain Delta 399 was expressed in a methionine auxotrophic E. coli strain B834(DE3) grown in LeMaster medium (18) supplemented with 25 µg/ml Se-methionine, and the protein was purified similarly to the native protein. X-ray diffraction data for the native and the single-site selenomethionine substitution crystals were collected (Table I), respectively, by an RAXIS-IV imaging plate detector equipped with a Rigaku rotating anode generator (50 kV, 100 mA) and a Brandeis B2 (1 × 1) CCD-based detector at the National Synchrotron Light Source beamline X12-C. The resulting images were processed using HKL (19). One surface selenium site (SeMet447 of alpha C) was determined by SOLVE (20). RESOLVE (21) was then used to modify the electron density map at 2.5-Å resolution (overall figure of merit 0.54). The modified map was of excellent quality to place amino acids 411-554 of MBD4 into the recognizable densities by using the graphic program O (22). Electron density was not observed for the first 11 residues (400-410 of the full-length protein). The resulting model was refined to 2.09 Å resolution using X-PLOR (23) (Table I), with a final crystallographic R-factor of 0.213 and R-free of 0.263 (for 9% of total 21,552 reflections).

                              
View this table:
[in this window]
[in a new window]
 
Table I
X-ray data collection and structural refinement statistics

Preparation of E. coli Extract-- The His-tagged full-length MBD4, Delta 48, MBD domain (amino acids 49-187), glycosylase domain Delta 399, and Delta 428 were all transformed into an E. coli strain BH161, which carries ung- and a copy of T7 RNA polymerase (24). Ten milliliters of culture was grown from each clone in LB media supplemented with 100 µg/ml ampicillin (full-length MBD4) or 50 µg/ml kanamycin (all MBD4 fragments) at 37 °C until the A600 reached 0.6. The cultures were induced by adding isopropyl-1-thio-beta -D-galactopyranoside to a final concentration of 0.5 mM. After incubation at 37 °C for 3 h, the cells were recovered by centrifugation, and the cell pellets were washed with a buffer containing 20 mM Tris-HCl, pH 7.6, and 0.1 mM EDTA. Cells were resuspended in 0.5 ml of extraction buffer (20 mM Tris-HCl, pH 7.8, 0.1 mM EDTA, 5 mM 2-mercaptoethanol) containing 1 mg/ml lysozyme and incubated on ice for 15 min. Finally, the cells were broken by sonication on ice, and cell-free lysate was recovered following centrifugation at 12,000 × g for 15 min at 4 °C. Protein concentration in the extracts was determined using the Bradford Reagent (Bio-Rad).

Preparation of the Labeled DNA Substrate-- The following oligonucleotides were obtained from Invitrogen:

T-oligo, 5'-GACTGGCTGCTCCTGGGCGAAGTGCC-3';

G-oligo, 5'-GGGCACTTCGCCCGGGAGCAGCCAGTC-3'.

The oligonucleotides were gel-purified prior to their use. The T-oligo was labeled at the 5' end using T4 polynucleotide kinase (New England Biolabs) in the presence of [gamma -32P]ATP (specific activity 6000 Ci/mmol, PerkinElmer Life Sciences). The reaction was terminated by heating it to 65 °C for 20 min. The labeled T-oligo was mixed with 3-fold molar excess of the unlabeled G-oligo in the STE buffer (150 mM NaCl, 10 mM Tris-HCl, pH 8.0, and 1 mM EDTA). The mixture was heated to 95 °C for 3 min and then slowly cooled to room temperature over a period of 2-3 h to promote duplex formation. The unincorporated [gamma -32P]ATP was removed from the labeled duplex by passage through a G-50 micro column (Amersham Biosciences).

DNA Glycosylase Assay-- Twenty nM labeled duplex was equilibrated with nicking buffer (10 mM Tris-HCl, pH 8.0, 5 mM EDTA, 1 mM DTT, and 0.1 mg/ml bovine serum albumin), and the reactions were initiated by adding 100 ng of purified MBD4 variants (Fig. 5A) or 2 µg of cell-free extract (Fig. 5B). Following incubation at 37 °C for 1 h, the reaction was stopped by heating to 95 °C for 7 min in the presence of 0.1 M NaOH. Subsequently, 8 µl of gel loading dye (80% formamide, 10 mM EDTA, 1 mg/ml each of xylene cyanol and bromphenol blue) was added to the samples which were then heated to 95 °C and electrophoresed in 20% sequencing gel. The gel was exposed to a PhosphorImager screen (Amersham Biosciences), and the reaction products were quantified using ImageQuant software.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

MBD4 Glycosylase Domain Structure-- The overall structure of MBD4 glycosylase domain consists of 11 helices (alpha A to alpha K) (Fig. 1B) forming a single domain with a cleft in the middle (Fig. 2). Structural comparison with other DNA glycosylases (Fig. 3, A and B) reveals that the MBD4 glycosylase domain belongs to the helix-hairpin-helix (HhH) DNA glycosylase superfamily (25), named after a conserved structural motif alpha H-hairpin loop-alpha I (shown in red in Fig. 2A). The six helices before the HhH motif (alpha B to alpha G in green) are highly conserved structural elements among family members, forming the bottom of the cleft in the orientation shown (Fig. 2A). Among the known HhH enzymes, MBD4 has the shortest sequence following the HhH motif (Fig. 1B). The C-terminal helices alpha J and alpha K, the short N-terminal helix alpha A, and its 12-residue preceding loop, the HhH motif, come together to form a hydrophobic core (Fig. 2C), forming the top of the cleft.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 1.   A, schematic representation of mouse MBD4. Two stable fragments (shaded) were identified by limited proteolysis. Below the full-length mouse MBD4 are the depicted protein fragments (Delta 48, MBD, glycosylase domain Delta 399, and Delta 428) used in this study. B, structure-guided sequence alignment of three MBD4 glycosylase domains (mouse, AAC68878; human, AAC68879; and Gallus, AAF68981) and five HhH glycosylases. We note that the reported MBD4 homolog in chickens only contains the glycosylase domain and has no consensus sequence for the N-terminal MBD (10). The secondary structure of MBD4 is indicated above the sequence and colored the same as in Fig. 2A. The dashed lines indicate gaps introduced to optimize alignments, and MBD4 has the shortest loop prior to the HhH motif. The dots indicate extra residues outside the glycosylase domain. The residues in the active site, proposed to interact with the extrahelical target nucleotide, are colored to match their associated region. The residues marked by * above the sequence are discussed in the text. The deletion mutants made in human MBD4 (10, 33) and mouse MBD4 (this study) are indicated by arrows. The four differences between mouse and human MBD4 sequences are boxed.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 2.   Structure of MBD4 glycosylase domain. A, stereo view of Ribbon (36) diagram. The protein is colored according to Fig. 1B. The proposed thymine recognition residues Gln423 (orange) and Tyr514 (red), and the catalytic Asp534 (cyan) are shown in ball-and-stick model. B, two orthogonal views of solvent-accessible Grasp (37) surface with charge distribution (blue for positive charge, and red for negative charge). Left, the protein is shown in a similar orientation as in A. Right, the cleft predicted to hold the active site is visible after rotation ~90° on the vertical axis. C, stereo view of the hydrophobic core formed by the N-terminal loop and helix alpha A (orange), helix alpha I of HhH motif (red), and the C-terminal helices alpha K and alpha J (cyan). The hydrophobic side chains are shown in ball-and-stick model, colored to match their associated region. D, stereo view of difference electron density (blue) contoured at 3.0sigma above the mean, superimposed with Val422, Gln423, and Tyr514, and three associated water molecules.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 3.   Structural comparison of HhH glycosylases. A, superimposition of MBD4 glycosylase domain (colored according to Fig. 1B) and MutY (gray; Protein Data Bank code 1MUD). MutY (29), as well as EndoIII (30) and MIG (28), contains a C-terminal [4Fe-4S] cluster (shown in space-filling model). B, superimposition of MBD4 glycosylase domain and AlkA (gray; Protein Data Bank code 1DIZ). AlkA (26) and hOGG1 (27) contain an additional N-terminal beta -sheet domain, and a 13- or 15-residue insertion between alpha C and alpha D (see Fig. 1B). C, superimposition of two DNA binding loops between MBD4 (red and green) and AlkA (gray). The Gly-rich hairpin loop of HhH motif is indicated by conserved Gly510 and Gly512 of MBD4. The minor groove wedge (Leu125 in AlkA), which assists in base flipping, superimposed on Arg442 of MBD4 in the loop between helices alpha B and alpha C (see Fig. 1B). D, based on the superimposition shown in C, the MBD4 glycosylase domain is docked to DNA from the minor groove side. E, the MBD domain of MBD4 has not yet been structurally characterized; however, the NMR solution structure of the MBD domain of MBD1 was shown to bind DNA from the major groove side (13).

Model of the MBD4-DNA Complex-- The high degree of structural similarity among HhH glycosylases allowed us to create a model of the MBD4 glycosylase domain bound to DNA. By using the coordinates of the AlkA-DNA (26) or hOGG1-DNA (27) complexes, we superimposed the protein components, and then the DNA was positioned over the surface of MBD4 with the cleft. Previous modeling studies of other HhH glycosylases MutY and EndoIII suggested that they bind to DNA in a manner similar to that of AlkA (26). Our modeling suggests that the MBD4 glycosylase domain also binds DNA similarly to AlkA and hOGG1, which bind DNA via the minor groove and bend it ~70° at the damaged base (26, 27).

The residues that contact the DNA backbone in the hOGG1 and AlkA structures occupy similar positions in the free MBD4 structure (Fig. 3C), and the MBD4 glycosylase domain could contact bent DNA without major physical distortion of the protein component (Fig. 3D). Two important DNA-binding loops are superimposed, the loop between helices alpha B and alpha C and the Gly-rich hairpin loop of HhH motif (Fig. 3C). Arg442 of MBD4, as well as Arg47 of MIG (28), is in the same position as Leu125 of AlkA (or Asn149 of hOGG1) that fills the space in the DNA duplex vacated by the flipped nucleotide. Thr443 of MBD4 is in the same position as Asn150 of hOGG1 that makes main chain contacts to the phosphate groups 3' to the flipped nucleotide. Ser444 of MBD4 is in the position of Asn151 of hOGG1 that forms hydrogen bonds with the base 5' immediate to the flipped nucleotide. It seems that the loop between helices alpha B and alpha C contains residues (Arg442-Thr443-Ser444) important for DNA binding and base flipping.

Mechanisms for Recognition of Flipped Bases and Catalysis-- First, where is the active site? In analogy to the AlkA-DNA (26) and hOGG1-DNA (27) complexes, the MBD4 cleft defines the location of the active site (Fig. 4A). The target nucleotide is likely to be flipped out from the DNA helix into the active-site cleft of the enzyme, in a similar manner to AlkA or hOGG1. The structural superimposition of the HhH glycosylase-DNA complexes and the unbound MBD4 reveals several informative features. Interestingly, the flipped base can only be docked into the active site by stacking the base between the side chains of Leu440 of alpha B and Lys536 of alpha K (Fig. 4B). Although these residues are not conserved in HhH glycosylases, similar stacking appears to be conserved: in hOGG1 8-oxoguanine is between Cys253 and Phe319 (27) and in MutY adenine soaked into the crystal lies between Leu40 and Met185 (29). Leu440 of MBD4 corresponds to Leu40 of MutY (Figs. 1B and 4E), whereas MutY Met185 corresponds to Phe319 of hOGG1.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 4.   The active-site cleft and where the flipped, mismatched thymine will bind. A, close-up view of the cleft, where Asp534 is colored in red; Tyr514, Gln423, and Val422 are colored in green, and Ile449, Gly445, and Leu440 are in yellow. B, the thymine (yellow) is docked in between Leu440 and Lys536. C, the Watson-Crick pairing edge of thymine (O-2, N-3, and O-4) is aligned with three ordered water molecules (green) that make hydrogen bonds with Tyr514, Gln423, and Val422. The C-5 methyl group would make van der Waals contact with Ile449 and Gly445. The C1' of the target sugar would be in a direct contact with the carboxylate group of Asp534. The atom spheres are colored in red (oxygen), blue (nitrogen), and gray (carbon); the chemical bonds are colored in gray for the protein residues and yellow for thymine. D, schematic drawing of adenine-specific interactions in MutY (29). E, stereo view of superimposition of active site residues of MutY (gray) and the proposed MBD4 active site residues (colored according to Fig. 1B). F, schematic drawing of proposed thymine-specific interactions in MBD4.

A second question is where the key catalytic residues are located. Asp534, the last residue prior to helix alpha K (Fig. 1B), is in a position structurally equivalent to the catalytically important Asp238 of AlkA (26), Asp268 of hOGG1 (27), Asp138 of MutY (29), and Asp138 of EndoIII (30). Two mechanisms have been suggested for the function of this structurally conserved aspartic acid in HhH glycosylases: (i) it activates a catalytic nucleophile, which is either a water (29) or the epsilon -amino group of a lysine (27), for the attack on the deoxyribose C1' carbon atom of the target nucleotide; or (ii) it directly assists base removal by protonating the leaving group of the substrate sugar (26). In the docking model of MBD4-thymine (Fig. 4C), the C1' position of a modeled substrate is in direct contact (~3.0 Å) with the carboxylate of Asp534, which would favor the second (protonation) mechanism.

A third question regarding the MBD4 action is how it distinguishes an A:T pair from a G:T. Although it is possible that the protein distinguishes G:T from an A:T because of their differing geometries, it is also possible that it may make specific contacts with the guanine in a manner similar to E. coli MUG (31) or hOGG1 (27); Arg486 of MBD4 is in the same position as Arg204 of hOGG1 that forms hydrogen bonds in the minor groove side with the G on the opposite strand of the flipped nucleotide. A detailed answer to this question must await the availability of a MBD4-DNA co-crystal structure.

Thymine and Uracil-- How does the flipped base specifically bound in the active site? In MutY the adenine soaked into the crystal are recognized by Glu37 and Gln182 (29) (Fig. 4D). Structural superimposition between MutY and MBD4 (Fig. 3A) indicates the side chains of Gln-423 and Tyr514 of MBD4 are in the vicinity of the adenine-specific interacting side chains of MutY (Fig. 4E).

In MBD4, the two polar residues (Gln423 of alpha A and Tyr514 of alpha I) and three hydrophobic residues (Val422 prior to alpha A, Gly445, and Ile449 of alpha C) line in the cleft next to the catalytic Asp534 (Fig. 4A). We suggest that these amino acids are the major determinants of specificity after docking the flipped thymine into the binding pocket. In the absence of the target nucleotide, the active site is occupied by ordered water molecules (Fig. 2D), which lie almost in a plane and directly interact with Tyr514, Gln423, and Val422 (Fig. 4C). We docked a thymine with its Watson-Crick pairing edge (O-2, N-3, and O-4) occupying three water sites (Fig. 4C). The OH group of Tyr514 can make one hydrogen bond with the O-2 atom, the side chain carbonyl C = O of Gln423 can make a hydrogen bond to the protonated N-3-H. In addition, the main chain N-H group of Val422 can make a hydrogen bond to the O-4 atom. Gly445 and Ile449 form a surface hydrophobic patch near the end of the cleft, in a perfect position to accommodate the methyl group of thymine. Of all contacts made to the thymine base (Fig. 4F), the hydrophobic-methyl interaction will be absent for a uracil base.

Interestingly, Glu, Gln, or Tyr are often found in the active site of the HhH glycosylases. A glutamate is found in MIG (Glu42; Ref. 28) and TAG (Glu38; Ref. 32) in the equivalent position as Glu37 of MutY; the corresponding main chain position in MBD4 is Thr437 (helix alpha B), whose side chain points opposite as that of Glu37 in MutY (Fig. 4E) and makes a hydrogen bond with main chain carbonyl oxygen atom of Leu434. A tyrosine is proposed for interacting target thymine in MIG (28) (Tyr126 occupying equivalent position as Tyr514 of MBD4 in helix alpha I), for interacting target 3-methyladenine in AlkA (26) (Tyr222 from an alpha I-equivalent helix, i.e. the second helix of HhH motif), and in TAG (32) (Tyr16 of an N-terminal helix). A glutamine is common to MutY (Gln182) and hOGG1 (Gln315) in recognizing their substrate base, adenine and 8-oxoguanine, respectively; both Gln182 of MutY and Gln315 of hOGG1 are located in a C-terminal helix outside of the structurally homologous regions among the HhH glycosylases shown in Fig. 1B. Although MBD4 does not have an equivalent C-terminal helix, the N-terminal and C-terminal regions of all structurally characterized HhH glycosylases are folded together, above the cleft as shown in Fig. 3; and in the case of MBD4, Gln423 is from the N-terminal helix alpha A and its side chain occupies a similar position as that of Gln from the C-terminal helix.

DNA Glycosylase Activity of MBD4 N-terminal Truncations-- Among the known HhH enzymes, MBD4 has the longest N-terminal sequence before the glycosylase domain (for examples, see Fig. 1B). Zhu et al. (10) analyzed a series of N-terminal deletion mutants of human MBD4, and the results are consistent with our glycosylase domain structure presented here. In that study, N-terminal deletions of up to 65% of the total length of MBD4 retain the DNA glycosylase activity. The smallest fragment that retained activity, Delta N433 (10), is very similar in size to our glycosylase domain determined by proteolysis (see Fig. 1B).

We used a DNA duplex containing a G:T within a CpG sequence context as the substrate to test the glycosylase activities of purified full-length MBD4 and several of its deletion derivatives. The T-containing strand was radiolabeled, and the excision of this base was monitored by gel electrophoresis. Typical results are presented in Fig. 5A and show that in addition to the full-length MBD4, the Delta 399 mutant used for crystallography is an active thymine DNA glycosylase. A construct missing the first 48 amino acids of the full-length protein (Delta 48) has less activity, but the construct containing only the MBD segment of the protein (amino acids 48-187) has no detectable activity (Fig. 5A). We also measured the activity of all MBD4 constructs in crude cell extract by expressing the proteins in a strain lacking the endogenous uracil glycosylase gene (ung-) to minimize background. Full-length MBD4, Delta 48, and Delta 399 all have detectable activity in this assay (Fig. 5B).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 5.   Glycosylase activities of MBD4 N-terminal truncations. A, thymine excision activities of purified full-length MBD4 and its deletion derivatives are shown. One hundred nanograms of the His-tagged or GST-tagged (Delta 428) versions of the proteins were used with 20 nM radiolabeled duplex containing a G:T. The products of the reaction were separated on a sequencing gel, and the gel was scanned with a PhosphorImager. The PhosphorImager scan is shown. B, glycosylase activities in cell extracts prepared from overproducers of MBD4 variants. Thymine excision activities in the cell extracts of the overproducers of full-length MBD4 and its deletion derivatives are shown. Cell extracts containing 2 µg of total proteins were used with 20 nM radiolabeled duplex containing a G:T. The products of the reaction were separated on a sequencing gel, and the gel was scanned with a PhosphorImager. The released product as a percentage of total labeled DNA is shown.

Petronzelli et al. (33) have reported that a deletion of the first 454 amino acids of the human MBD4 still retained its enzymatic activity. The murine MBD4 equivalent to this deletion would be missing 428 N-terminal residues (Fig. 1B), which include helix alpha A and its preceding loop that provides part of the hydrophobic core above the cleft (Trp412, Pro414, Pro415, Pro418, and Phe419; Fig. 2C) and Val422 and Gln423 that are proposed to contact the target thymine (Fig. 4C). Thus the results reported by Petronzelli et al. (33) are not compatible with the crystal structure and are surprising.

To resolve these discrepancies, we attempted to duplicate the result of Petronzelli et al. (33) by making the equivalent murine MBD4 truncation (Delta 428; Fig. 1) and fusing it to a six histidine tag or GST tag. We were unable to detect any expression of the His-tagged Delta 428 protein, either by Coomassie staining or anti-His tag antibody (data not shown), whereas all other MBD4 fragments were expressed and soluble under the same conditions. Not surprisingly, no glycosylase activity was detected in the extract of Delta 428 construct using the ung- strain (Fig. 5B). The GST-tagged Delta 428 was expressed to high level, but most of the protein was insoluble (data not shown). However, we did manage to partially purify some GST-Delta 428 fusion protein using a glutathione affinity column and a HiTrap Q column. The protein was heavily associated with Hsp60 (data not shown), an indication that the protein may not be folded properly. When the GST-Delta 428 protein was tested for glycosylase activity, none was detected (Fig. 5A). The observation that Delta 428 mutant does not fold properly is consistent with the important structural roles of the missing residues. In addition, although sequence similarity of MBD4 to other glycosylases starts at helix alpha B, MutY, MIG, EndoIII, and TAG all have N-terminal extensions similar in size to Delta 399 of MBD4 (Fig. 1B). We do not know the origin of the discrepancy between our data and that of Petronzelli et al. (33), as the sequences of human Delta 454 and mouse Delta 428 deletions are almost 100% identical except 4 residues (see Fig. 1B). One possibility is that the pET28b vector (Novagen) used for the human Delta 454 construct would add at least 10 additional residues besides the 6 histidines at the N terminus. These residues may fortuitously substitute the natural MBD4 residues and allow folding and enzymatic activity.

The activity of the Delta 399 deletion was easiest to detect in the extracts, whereas the full-length MBD4 and the Delta 48 construct displayed relatively poor activity (Fig. 5B). The lower activity of the full-length MBD4 in cell-free extracts was surprising but reproducible. It is noted that the MBD domain of MBD4 binds DNA with G:T mismatches (1), and it is possible that both the MBD and the glycosylase domains compete for the DNA substrate. Regardless, it is clear from these data that the Delta 399 construct of the murine MBD4, which has almost the same N-terminal extension as the MutY, MIG, EndoIII, and TAG, is a stable protein fragment with substantial glycosylase activity.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have described the crystallographic structure of the glycosylase domain of the methyl-CpG-binding protein MBD4. The structure reveals that the MBD4 glycosylase domain belongs to the HhH DNA glycosylase superfamily. Modeling studies suggest that MBD4 glycosylase domain, similar to that of AlkA and hOGG1 HhH glycosylases, binds DNA from the minor groove side (Fig. 3D).

Unlike other HhH glycosylases, MBD4 contains an additional DNA binding domain, the MBD, near its N terminus. An NMR solution structure of the MBD domain from human MBD1, in complex with methylated DNA, revealed that the MBD domain contacts both methyl groups of methyl-CpG site via the major groove of B-form DNA (13) (Fig. 3E). This is consistent with the observation that of the DNA sequence tested, only the fully methylated CpG or the methylated mismatch 5mCpG/TpG (both contain two methyl groups in the major groove) is bound by the MBD of MBD4 (1). Because all structurally characterized HhH glycosylases in complex with DNA appear to bind DNA exclusively via the minor groove, it is attractive to think that the MBD and the glycosylase domains of MBD4 would come together at 5mCpG/TpG mismatches to engulf DNA from opposite directions (28). However, because the MBD domain does not bend DNA (13), whereas all HhH glycosylases appear to significantly bend DNA and flip the target, it is not clear how DNA would be bent when both domains bind together. Alternatively, perhaps the two domains separated by ~200 residues bind DNA at adjacent but non-overlapping sites. The function of the MBD domain in MBD4 may be to target the glycosylase activity to regions of heavily methylated DNA as methyl-CpG dinucleotides tend to occur in clusters (reviewed in Ref. 34), so the tethered glycosylase domain could sample nearby sites for G:T mismatches. This would raise the local concentration of glycosylase activity in regions where methylated mismatch 5mCpG/TpG is most likely to occur.

The active-site cleft of the glycosylase domain suggests a base flipping mechanism for accessing the damaged or mispaired base (reviewed in Ref. 35), the mismatched base should be swung completely out of the DNA helix by torsional rotation of its flanking sugar-phosphate backbones so as to occupy the active-site cleft of MBD4. The structure also reveals candidate residues for catalysis (Asp534), for thymine (or uracil)-specific recognition hydrogen bonding (Tyr514, Gln423, and Val422), for the methyl group of thymine (Ile449 and Gly445), and for the stacking stabilization of the flipped base (Leu440 and Lys536). With this information, our structure provides useful starting points for more detailed studies of this interesting enzyme.

    ACKNOWLEDGEMENTS

We thank Dr. Adrian Bird (University of Edinburgh) for providing the constructs to overexpress mouse MBD4; Drs. Anand Saxena and Dieter Schneider (Brookhaven National Laboratory) and John R. Horton (Emory University) for help with x-ray data collection at beamlines X12-C and X26-C in the National Synchrotron Light Source; and Drs. Robert Blumenthal (Medical College of Ohio) and Paul Wade (Emory University) for critical comments on the manuscript.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants GM49245 (to X. C.) and GM57200 (to A. S. B) and the Georgia Research Alliance.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The atomic coordinates and the structure factors (code 1NGN) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

Both authors contributed equally to this work.

** To whom correspondence should be addressed: Dept. of Biochemistry, Emory University, 1510 Clifton Rd., Atlanta, GA 30322. Tel.: 404-727-8491; Fax: 404-727-3746; E-mail: xcheng@emory.edu.

Published, JBC Papers in Press, November 26, DOI 10.1074/jbc.M210884200

    ABBREVIATIONS

The abbreviations used are: MBD, methyl-CpG binding domain; 5mC, 5-methylcytosines; TDG, thymine-DNA glycosylase; GST, glutathione S-transferase; DTT, dithiothreitol.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Hendrich, B., Hardeland, U., Ng, H.-H., Jiricny, J., and Bird, A. (1999) Nature 401, 301-304[CrossRef][Medline] [Order article via Infotrieve]
2. Millar, C. B., Guy, J., Sansom, O. J., Selfridge, J., MacDougall, E., Hendrich, B., Keightley, P. D., Bishop, S. M., Clarke, A. R., and Bird, A. (2002) Science 297, 403-405[Abstract/Free Full Text]
3. Bellacosa, A., Cicchillitti, L., Schepis, F., Riccio, A., Yeung, A. T., Matsumoto, Y., Golemis, E. A., Genuardi, M., and Neri, G. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3969-3974[Abstract/Free Full Text]
4. Riccio, A., Aaltonen, L. A., Godwin, A. K., Loukola, A., Percesepe, A., Salovaara, R., Masciullo, V., Genuardi, M., Paravatou-Petsotas, M., Bassi, D. E., Ruggeri, B. A., Klein-Szanto, A. J., Testa, J. R., Neri, G., and Bellacosa, A. (1999) Nat. Genet. 23, 266-268[CrossRef][Medline] [Order article via Infotrieve]
5. Neddermann, P., Gallinari, P., Lettieri, T., Schmid, D., Trung, O., Hsuan, J. J., Wiebauer, K., and Jiricny, J. (1996) J. Biol. Chem. 271, 12767-12774[Abstract/Free Full Text]
6. Krokan, H. E., Nilsen, H., Skorpen, F., Otterlei, M., and Slupphaug, G. (2000) FEBS Lett. 476, 73-77[CrossRef][Medline] [Order article via Infotrieve]
7. Nilsen, H., Haushalter, K. A., Robins, P., Barnes, D. E., Verdine, G. L., and Lindahl, T. (2001) EMBO J. 20, 4278-4286[Abstract/Free Full Text]
8. Saparbaev, M., and Laval, J. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8508-8513[Abstract/Free Full Text]
9. Petronzelli, F., Riccio, A., Markham, G. D., Seeholzer, S. H., Stoerker, J., Genuardi, M., Yeung, A. T., Matsumoto, Y., and Bellacosa, A. (2000) J. Biol. Chem. 275, 32422-32429[Abstract/Free Full Text]
10. Zhu, B., Zheng, Y., Angliker, H., Schwarz, S., Thiry, S., Siegmann, M., and Jost, J.-P. (2000) Nucleic Acids Res. 28, 4157-4165[Abstract/Free Full Text]
11. Bird, A. P., and Wolffe, A. P. (1999) Cell 99, 451-454[Medline] [Order article via Infotrieve]
12. Wade, P. A. (2001) Oncogene 20, 3166-3173[CrossRef][Medline] [Order article via Infotrieve]
13. Ohki, I., Shimotake, N., Fujita, N., Jee, J.-G., Ikegami, T., Nakao, M., and Shirakawa, M. (2001) Cell 105, 487-497[CrossRef][Medline] [Order article via Infotrieve]
14. Ohki, I., Shimotake, N., Fujita, N., Nakao, M., and Shirakawa, M. (1999) EMBO J. 18, 6653-6661[Abstract/Free Full Text]
15. Wakefield, R. I. D., Smith, B. O., Nan, X., Free, A., Soteriou, A., Uhrin, D., Bird, A. P., and Barlow, P. N. (1999) J. Mol. Biol. 291, 1055-1065[CrossRef][Medline] [Order article via Infotrieve]
16. Hendrich, B., and Bird, A. (1998) Mol. Cell. Biol. 18, 6538-6547[Abstract/Free Full Text]
17. Dong, A., Yoder, J. A., Zhang, X., Zhou, L., Bestor, T. H., and Cheng, X. (2001) Nucleic Acids Res. 29, 439-448[Abstract/Free Full Text]
18. Hendrickson, W. A., Horton, J. R., and LeMaster, D. M. (1990) EMBO J. 9, 1665-1672[Abstract]
19. Otwinowski, Z., and Minor, W. (1997) Methods Enzymol. 276, 307-326
20. Terwilliger, T. C., and Berendzen, J. (1999) Acta Crystallogr. Sect. D Biol. Crystallogr. 55, 849-861[CrossRef][Medline] [Order article via Infotrieve]
21. Terwilliger, T. C. (2000) Acta Crystallogr. Sect. D Biol. Crystallogr. 56, 965-972[CrossRef][Medline] [Order article via Infotrieve]
22. Jones, T. A., and Kjeldgard, M. (1997) Methods Enzymol. 277, 173-208[CrossRef]
23. Brünger, A. T. (1992) X-PLOR: A System for X-ray Crystallography and NMR, version 3.1 , Yale University, New Haven, CT
24. Beletskii, A., Grigoriev, A., Joyce, S., and Bhagwat, A. S. (2000) J. Mol. Biol. 300, 1057-1065[Medline] [Order article via Infotrieve]
25. Nash, H. M., Bruner, S. D., Scharer, O. D., Kawate, T., Addona, T. A., Spooner, E., Lane, W. S., and Verdine, G. L. (1996) Curr. Biol. 6, 968-980[Medline] [Order article via Infotrieve]
26. Hollis, T., Ichikawa, Y., and Ellenberger, T. (2000) EMBO J. 19, 758-766[Abstract/Free Full Text]
27. Bruner, S. D., Norman, D. P. G., and Verdine, G. L. (2000) Nature 403, 859-866[CrossRef][Medline] [Order article via Infotrieve]
28. Mol, C. D., Arvai, A. S., Begley, T. J., Cunningham, R. P., and Tainer, J. A. (2002) J. Mol. Biol. 315, 373-384[CrossRef][Medline] [Order article via Infotrieve]
29. Guan, Y., Manuel, R. C., Arvai, A. S., Parikh, S. S., Mol, C. D., Miller, J. H., Lloyd, S., and Tainer, J. A. (1998) Nat. Struct. Biol. 5, 1058-1064[CrossRef][Medline] [Order article via Infotrieve]
30. Thayer, M. M., Ahern, H., Xing, D., Cunningham, R. P., and Tainer, J. A. (1995) EMBO J. 14, 4108-4120[Abstract]
31. Barrett, T. E., Scharer, O. D., Savva, R., Brown, T., Jiricny, J., Verdine, G. L., and Pearl, L. H. (1999) EMBO J. 18, 6599-6609[Abstract/Free Full Text]
32. Drohat, A. C., Kwon, K., Krosky, D. J., and Stivers, J. T. (2002) Nat. Struct. Biol. 9, 659-664[CrossRef][Medline] [Order article via Infotrieve]
33. Petronzelli, F., Riccio, A., Markham, G. D., Seeholzer, S. H., Genuardi, M., Karbowski, M., Yeung, A. T., Matsumoto, Y., and Bellacosa, A. (2000) J. Cell. Physiol. 185, 473-480[CrossRef][Medline] [Order article via Infotrieve]
34. Jones, P. A., and Takai, D. (2001) Science 293, 1068-1070[Abstract/Free Full Text]
35. Roberts, R. J., and Cheng, X. (1998) Annu. Rev. Biochem. 67, 181-198[CrossRef][Medline] [Order article via Infotrieve]
36. Carson, M. (1997) Methods Enzymol. 277, 493-505
37. Nicholls, A., Sharp, K. A., and Honig, B. (1991) Protein Struct. Funct. Genet. 11, 281-296


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.